Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announces that a methods paper on the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) clinical trial design has been published in the European Journal of Heart Failure (EJHF 2015).
CHART-1 (Congestive Heart failure Cardiopoietic Regenerative Therapy) is a patient prospective, controlled multi-centre, randomized, double-blinded Phase III clinical trial comparing treatment with C-Cure® to a sham treatment. The trial has recruited 240 patients with chronic advanced symptomatic heart failure in Europe and Israel. The primary endpoint of the trial is a composite endpoint including mortality, morbidity, quality of life, Six Minute Walk Test and left ventricular structure and function at nine months post-procedure. The next milestone in the clinical trial will be the release of the full clinical data set, anticipated for mid-2016.
Dr. Christian Homsy, CEO of Celyad, said: “The publication of the CHART-1 methods paper in the European Journal of Heart Failure is a scientific acknowledgement of the work that has been done around the design of our clinical trial for ischemic heart failure. We are proud of this achievement and we thank all the people who have been involved in the writing process.”
Dr. Warren Sherman, Chief Medical Officer at Celyad, added: “The CHART-1 Study brings together two major scientific innovations: cells designed specifically for cardiac repair (C-Cure) and an injection catheter (C-CathezTM) designed specifically to increase the retention of cells by the heart. It is most gratifying that such a prestigious journal has chosen to publish this paper.”
Download Celyad’s abstract on Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design, please click here (pdf – 358 Ko).
